Adjuvant treatment after surgery for pancreatic neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests whether giving a combination of two chemotherapy drugs after surgery can reduce the chance that your pancreatic neuroendocrine tumor comes back. It is for people who have had their tumor completely removed but have a higher risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove a well-differentiated pancreatic neuroendocrine tumor (a type of slow-growing tumor).
- Your tumor was completely removed with no signs of cancer left behind (called R0 resection).
- It has been less than 4 months since your surgery.
- You have not had any previous chemotherapy or radiation for this tumor.
- Your tumor shows certain features that make it more likely to come back (based on its size, grade, and whether it spread to lymph nodes).
- You are generally healthy (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial tests whether adding a targeted drug (nimotuzumab) to standard chemotherapy after surgery can help prevent pancreatic cancer from coming back. It is designed for people who have had their pancreatic cancer completely or nearly completely removed.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic Neuroendocrine Tumors (pNET) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.